Vaccines Expressing the Innate Immune Modulator EAT-2 Elicit Potent Effector Memory T Lymphocyte Responses despite Pre-Existing Vaccine Immunity

Yasser Ali Aldhamen, Sergey S. Seregin, Nathaniel J. Schuld, David P. W. Rastall, Chyong-jy J. Liu, Sarah Godbehere and Andrea Amalfitano

J Immunol 2012; 189:1349-1359; Prepublished online 27 June 2012; doi: 10.4049/jimmunol.1200736
http://www.jimmunol.org/content/189/3/1349

 Supplementary Material  http://www.jimmunol.org/content/suppl/2012/06/27/jimmunol.1200736.DC1

Why The JI?

• Rapid Reviews! 30 days* from submission to initial decision
• No Triage! Every submission reviewed by practicing scientists
• Speedy Publication! 4 weeks from acceptance to publication

*average

References  This article cites 47 articles, 13 of which you can access for free at: http://www.jimmunol.org/content/189/3/1349.full#ref-list-1

Subscription  Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription

Permissions  Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html

Email Alerts  Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts
Vaccines Expressing the Innate Immune Modulator EAT-2 Elicit Potent Effector Memory T Lymphocyte Responses despite Pre-Existing Vaccine Immunity

Yasser Ali Aldhamen,* Sergey S. Seregin,* Nathaniel J. Schuldt,* David P. W. Rastall,* Chyong-jy J. Liu,* Sarah Godbehere, and Andrea Amalfitano*†

The mixed results from recent vaccine clinical trials targeting HIV-1 justify the need to enhance the potency of HIV-1 vaccine platforms in general. Use of first-generation recombinant adenovirus serotype 5 (rAd5) platforms failed to protect vaccinees from HIV-1 infection. One hypothesis is that the rAd5-based vaccine failed due to the presence of pre-existing Ad5 immunity in many vaccinees. We recently confirmed that EAT-2–expressing rAd5 vectors uniquely activate the innate immune system and improve cellular immune responses against rAd5-expressed Ags, inclusive of HIV/Gag. In this study, we report that use of the rAd5-EAT-2 vaccine can also induce potent cellular immune responses to HIV-1 Ags despite the presence of Ad5-specific immunity. Compared to controls expressing a mutant SH2 domain form of EAT-2, Ad5 immune mice vaccinated with an rAd5-wild-type EAT-2 HIV/Gag-specific vaccine formulation significantly facilitated the induction of several arms of the innate immune system. These responses positively correlated with an improved ability of the vaccine to induce stronger effector memory T cell-biased, cellular immune responses to a coexpressed Ag despite pre-existing anti-Ad5 immunity. Moreover, inclusion of EAT-2 in the vaccine mixture improves the generation of polyclonal cytolytic CD8+ T cell responses as characterized by enhanced production of IFN-γ, TNF-α, cytotoxic degranulation, and increased in vivo cytolytic activity. These data suggest a new approach whereby inclusion of EAT-2 expression in stringent human vaccination applications can provide a more effective vaccine against HIV-1 specifically in Ad5 immune subjects. The Journal of Immunology, 2012, 189: 1349–1359.

H uman immunodeficiency virus/AIDS continues to be a significant health threat both in the United States and worldwide. The number of people globally living with HIV-1 was estimated to be 33.3 million in 2009 (1). HIV-1 infection is associated with high morbidity and mortality, contributing to 2 million deaths and 2.7 million people being newly infected worldwide (1). These facts emphasize the continued need to develop safe, effective, and easily administered vaccines against HIV-1. Most recently, a human clinical trial demonstrated that a prophylactic vaccine to HIV-1 may indeed be possible (2, 3). However, the results of that trial combined with some of the results derived from the Merck-sponsored STEP trial suggest that a more potent vaccine, capable of inducing greater levels of Ag-specific adaptive immune responses to HIV-1 Ags, will be needed to effectively prevent HIV-1 infections (4). Development of vaccines capable of inducing both HIV-1–specific neutralizing Ab as well as T cell responses (the latter in the hopes of reducing HIV-1 viral replication postinfection) has been a focus of HIV-1–targeted vaccine research in recent years (5–7). In particular, induction of potent effector memory T (T EM) lymphocyte responses by vaccines is hypothesized to be much more effective to protect vaccinees from infection with low levels of infectious virus typically present in the first hours and days following initial HIV-1/SIV exposure (8–10).

Recombinant adenovirus serotype 5 (rAd5)-based vaccines expressing several HIV-1 Ags have been shown to induce HIV-1–specific humoral, as well as potent cellular, immune responses in human trials (11, 12). However, pre-existing immunity against Ad5 is present in 50–90% of normal human adults (13). In vaccines given HIV-1–targeted Ad vaccines, the presence of pre-existing anti-Ad5 humoral and cellular immunity may have limited the overall efficacy of Ad5 HIV-1 vaccines in trial participants (11, 12, 14). Several approaches have therefore been developed to circumvent pre-existing anti-Ad5 immunity and/or to facilitate the induction of potent adaptive immune responses by Ad5-based vaccines in general. These approaches include the use of novel Ad5-based platforms (15, 16), modification of Ad5 structure (17), and the development of alternative serotype (human- or chimpanzee-derived) adenovirus-based vectors (18).

We have previously reported that an rAd5-based vaccine platform that expresses the signaling lymphocyte activation molecule (SLAM) family of receptors adaptor molecule, EAT-2, have superior qualities relative to current generation rAd5-based vaccines (19, 20). In recent years, there has been accumulating evidence implicating a critical role for SLAM family of receptors and signaling lymphocyte activation molecule-associated protein (SAP) family of adaptors in regulating both innate and adaptive

*Department of Microbiology and Molecular Genetics, Michigan State University, East Lansing, MI 48824; and †Department of Pediatrics, College of Osteopathic Medicine, Michigan State University, East Lansing, MI 48824

Received for publication March 5, 2012. Accepted for publication May 31, 2012.

A.A. was supported by the Michigan State University Foundation and by the Osteopathic Heritage Foundation. Y.A.A. was supported by a King Abdullah bin Abdulaziz scholarship, Ministry of Higher Education, Kingdom of Saudi Arabia.

Address correspondence and reprint requests to Dr. Andrea Amalfitano, Michigan State University, 4194 Biomedical and Physical Sciences Building, East Lansing, MI 48824. E-mail address: amalfit1@msu.edu

The online version of this article contains supplemental material.

Abbreviations used in this article: Ad, adenovirus; Ad5, adenovirus serotype 5; DC, dendritic cell; dpi, days postinjection; MFI, mean fluorescence intensity; SAP, signaling lymphocyte activation molecule-associated protein; SH, Src homology; SLAM, signaling lymphocyte activation molecule; Te2m, central memory T; Tem, effector memory T; vp, virus particle; WT, wild-type.

Copyright © 2012 by The American Association of Immunologists, Inc. 0022-1767/12/$16.00

www.jimmunol.org/cgi/doi/10.4049/jimmunol.1200736

The online version of this article contains supplemental material.

The Journal of Immunology
immunity (21). The members of the SLAM family of receptors were first identified as adhesion molecules on the surface of several hematopoietic cells. These receptors function as costimulatory molecules that initiate distinct signal-transduction networks in T cells, NK cells, and APCs (22). However, further functional and structural studies have demonstrated that SLAM receptors also function as critical regulators of immune cells, including NK cells, dendritic cells (DCs), neutrophils, macrophages, and platelets (22). Because EAT-2 is the only known SLAM-associated adaptor protein expressed in DCs and macrophages, it has been proposed that EAT-2 facilitates SLAM-dependent immunoregulatory function (such as proinflammatory cytokine expression) in these cell types (22). Based on these facts, we demonstrated that expression of EAT-2 from a vaccine platform triggers early activation of innate immune cells in vivo and consequently improved the induction of Ag-specific adaptive immune responses (19, 20). Specifically, Ad vaccine-mediated EAT-2 expression improved elaboration of beneficial cytokine and chemokine responses, enhanced the early activation of NK and NKT cells, and improved APC function by upregulating the expression of maturation markers, including CD40, CD80, CD86, MHC class II, and CCR7 (19). Improvements in innate immune system recruitment correlated with induction of superior cytolytic CD8+ T cell-mediated immune responses to several Ags, including HIV-1/Gag (19) and the malaria circumsporozoite protein (20).

Because EAT-2 functions as a potent T cell stimulator, we decided to examine the ability of rAd5-EAT-2 vaccines to induce potent HIV-1/Gag-specific cellular immune responses in the presence of pre-existing anti-Ad5–specific immunity, a situation that limits the induction of Ag-specific T cell responses by Ad vaccines in general (23). We also wanted to examine the role of the EAT-2 Src homology (SH)2 domain in modulating the innate and adaptive immune responses to a coadministered target Ag delivered by an Ad-based vaccine.

Materials and Methods

Vector construction

The rAd5-GFP, Ad5-null, Ad5-HIV/Gag, and Ad5-EAT-2 viruses were purified as previously described (19, 24). The rAd5-EAT-2 (R31Q) vector is identical to the rAd5-EAT-2 virus, except it additionally contains an arginine 31 to glutamine (EAT-2-R31Q) mutation in the EAT-2 SH2 domain as constructed as follows. Mutation at the indicated site was designed by using Vector NTI (Invitrogen, Carlsbad, CA). The open reading frame of the EAT-2 gene (GenBank accession no. NM_012009; http://www.ncbi.nlm.nih.gov/nuccore/148747581) was excised using primers flanked by XhoI and XbaI restriction endonucleases (New England BioLabs, Ipswich, MA) from a plasmid (Biomatik, Wilmington, DE) and subcloned into the pShuttle vector, which contains a CMV expression cassette. Direct sequencing and restriction enzyme mapping were carried out to confirm the integrity of the EAT-2 (R31Q) sequence. The resulting pAdTrack-EAT-2 (R31Q) shuttle plasmid was linearized with Pmel restriction enzyme and homologously recombined with the pAdEasy1 Ad5 vector genome, yielding pAd5-EAT-2 (R31Q). HEK293 cells were transfected with PacI-linearized plasmid, and viable virus was obtained and amplified after several rounds of expanding infection. rAd5-EAT-2 (R31Q) virus was purified using a CsCl2 gradient as previously described (25). To confirm that rAd5-EAT-2 (R31Q) vector expresses stable protein levels of EAT-2, we performed flow cytometry analysis to validate the expression of EAT-2 protein following rAd5-EAT-2 or rAd5-EAT-2 (R31Q) infection. At 72 h after infection, similar levels of EAT-2 protein were detected in both rAd5-EAT-2– and rAd5-EAT-2 (R31Q)–infected RAW264.7 cells (Supplemental Fig. 1).

All animals were found to be replication-competent adenovirus-free by both replication-competent adenovirus PCR (E1 region amplification) and direct sequencing methods as previously described (26).

Animal procedures

All animal procedures were approved by the Michigan State University Institutional Animal Care and Use Committee. Adult male wild-type (WT) BALB/c and C57BL/6 mice were purchased from The Jackson Laboratory (Bar Harbor, ME). For innate immune cell responses, i.m. injection of animals (8–10 wk old) consisted of injection (into the tibialis anterior of the right hind limb) of 30 μl PBS solution (pH 7.4) containing 2 × 10^10 total virus particles (vps) of either rAd5-GFP, Ad5-EAT-2, or rAd5-EAT-2 (R31Q) as previously described (27). Plasma and tissue samples were obtained and processed at the indicated times after injection as previously described (27). rAd5-null (an E1-, E3-, IAd5 vector not expressing any Ag) (two doses, in a 2-wk interval, of 1 × 10^10 vps) was injected i.m. in the right hind limb in a total of 30 μl PBS to generate animals with pre-existing Ad5 immunity (Ad5 preimmune animals) (Supplemental Fig. 2). Two immunizations with Ad5-null induced Ad5-neutralizing Ab titers that were >1/200, a level that closely parallels levels of pre-existing Ad5 immunity noted in human populations as previously described (26, 28, 29). To confirm that experimental and control groups developed equivalent amounts of anti-Ad5–specific immunity, blood samples were collected 1 d before vaccination (27 d after the last injection), and rAd5-null (27 d) ELISPOT analysis was performed for total Ad5-specific IgG was completed. Both experimental and control groups developed equal amounts of total Ad5-specific IgG Abs (Supplemental Fig. 3A). Fourteen days following the last Ad5-null injection, mice were randomly separated into three groups and i.m. vaccinated with rAd5-HIV/Gag, rAd5-GFP, rAd5-HIV/Gag + rAd5-EAT-2, or rAd5-HIV/Gag + rAd5-EAT-2 (R31Q) viruses (1 × 10^7 total vps). Mice were boosted with the similar doses at the indicated time points (Supplemental Fig. 2).

Isolation of splenocytes

Splenocytes from individual mice were harvested and processed as follows: spleen tissues were physically disrupted by passage through a 40-μm sieve, followed by RBC lysis using 2 ml ACK lysis buffer (Invitrogen) per homogenized spleen. Splenocytes were subsequently washed twice with RPMI 1640 (Invitrogen) supplemented with 10% FBS, 2 mM l-glutamine, and 1% penicillin/streptomycin/fungizone and then resuspended and counted.

In vitro cell culture

Murine RAW264.7 macrophages (ATCC TIB71) were maintained in DMEM supplemented with 10% FBS and penicillin/streptomycin following standard procedures. Suspensions of 3 × 10^6 cells were seeded into each of well-12-plates. The cells were then incubated with 600 μl culture medium alone or with medium containing rAd5-EAT-2 or rAd5-EAT-2 (R31Q) vectors at 20,000 multiplicities of infection for 48 h. EAT-2 expression was evaluated by Alexa Fluor 488 (Invitrogen)-conjugated EAT-2 Ab (sc-21572, Santa Cruz Biotechnology).

ELISPOT analysis

Splenocytes were harvested from individual mice and RBCs were lysed using ACK lysis buffer (Invitrogen). Ninety-six-well Multiscreen high protein binding Immobilon-P membrane plates (Millipore, Billerica, MA) were pretreated with ethanol, coated with mouse anti–IFN-γ or IL-2 capture Abs, incubated overnight, and blocked prior to the addition of 5 × 10^4 splenocytes per well. Ex vivo stimulation included the incubation of splenocytes in 100 μl media alone (unstimulated) or media containing 4 μg/ml Gag-specific peptides (Gag-AMQMLKETI constructed by GenScript International, St. Louis, MO) for 37°C, 5% CO2 incubation. The addition of plates was completed per the manufacturer’s protocol. Spots were counted and photographed by an automated ELISPOT reader system (Cellular Technology, Cleveland, OH). Ready-SET-Go! IFN-γ and IL-2 mouse ELISPOT kits were purchased from eBioscience (San Diego, CA).

Cell staining and flow cytometry

To evaluate the intracellular cytokine responses following rAd5-Gag and Ad5-EAT-2 covaccination, splenocytes from individual animals stained in situ with PE-Alexa 700 anti–CD4 (BD Biosciences, San Diego, CA), PerCP-Cy5.5-IL2 (Biolegend, San Diego, CA), and staining with PE-Cy7-anti–CD3, allophycocyanin-granzyme B, PE-perforin, FITC-IFN-γ, Pacific Blue-CD62L, PerCP-Cy5.5-CD127 (4 μg/ml) (all obtained from BD Biosciences, San Diego, CA), and PerCP-Cy5.5-IL-2 (BioLegend, San Diego, CA). We included a violet fluorescent reactive dye (VIVID; Invitrogen) as a viability marker to exclude dead cells from the analysis (30). For innate cell immunity studies, splenocytes were stained with various combinations of the following Abs: PE-CD69 (3 μg/ml), allophycocyanin-CD3, allophycocyanin-CD73, Alexa Fluor 700-CD8a, PE-Cy7-NK1.1, CD11c-PE-Cy7, and CD11b-allophycocyanin-CD11b (all obtained from BD Biosciences, San Diego, CA). PerCP-Cy5.5-IL-2 staining was performed with the appropriate Abs for 30 min, washed, and data were collected using an LSR II instrument and analyzed using FlowJo software. For tetramer staining, blood was isolated by retro-orbital bleeds, and PBMCs were
isolated using Lymphocyte-Mammal (Cedarlane Laboratories, Burlington NC). Tetramer staining of PMBCs was completed using a PE-conjugated MHC class I tetramer folded with the AMQMLKETI peptide generated at the National Institutes of Health Tetramer Core Facility.

**In vivo CTL assay**

An in vivo CTL assay was performed as previously described (19, 20). Briefly, Ad5 preimmune BALB/cJ mice (n = 5) were covaccinated with equivalent doses of rAd5-HIV/Gag with either rAd5-GFP, rAd5-EAT-2, or rAd5-EAT-2 (R31Q) (totaling 1 × 10^11 vps). Fourteen days following the boost vaccine, synthetic splenocytes were isolated and either pulsed with an irrelevant peptide specific to the Plasmodium falciparum circumsporozoite Ag (NYNDAGTNL) or with the HIV/Gag immunodominant AMQMLKETI peptide for 1 h at 37°C. Irrelevant peptide-pulsed cells were subsequently stained with 1 μM CFSE (CFSE\textsuperscript{high}), whereas Gag peptide-pulsed cells were stained with 10 μM CFSE (CFSE\textsuperscript{low}). Naïve and immunized mice were injected with equivalent amounts of both CFSE\textsuperscript{high}– and CFSE\textsuperscript{low}-stained cells (8 × 10^5 total cells/mouse) via the retro-orbital sinus. After 20 h, mice were terminally sacrificed and splenocytes were recovered and analyzed on an LSRII flow cytometer. FlowJo software was used to determine percentages of CFSE-stained cells as follows: % specific killing = 1 – [(% CFSE\textsuperscript{low} CFSE\textsuperscript{high})immunized/(% CFSE\textsuperscript{low} CFSE\textsuperscript{high})nonimmunized].

**Ab titering assay**

ELISA-based titering experiments were essentially completed as previously described (26, 28). In brief, 5 × 10^5 vps Ad5 vector per well or 0.2 mg recombinant Gag protein per well (each diluted in PBS) was used to coat wells of a 96-well plate overnight at 4°C. Plates were washed with PBS-Tween 20 (0.05%) solution, and blocking buffer (3% BSA in PBS) was added to each well and incubated for 1–3 h at room temperature. For titration of total IgG Abs, plasma from coinjected mice was diluted 1:10 to 1:2500 (Ad5) or 1:20 (Gag) in blocking buffer. Following dilution, plasma was added to the wells and incubated at room temperature for 1 h. Wells were washed with PBS-Tween 20 (0.05%), and HRP-conjugated rabbit anti-mouse Ab (Bio-Rad, Hercules, CA) was added at a 1:5000 dilution in blocking buffer. Following incubation, wells were washed, and TMB substrate (Bio-Rad) was added to each well, and the reaction was stopped with a 2 N sulfuric acid. Plates were read at 450 nm in a microplate spectrophotometer.

**Statistical analysis**

Statistically significant differences in toxicities associated with vaccine responses were determined using a one-way ANOVA with a Student–Newman–Keuls post hoc test (p value of <0.05 was deemed statistically significant). For ELISPOT analysis, a two-way ANOVA was used followed by Bonferroni post hoc test for flow cytometry, a one-way ANOVA with a Student–Newman–Keuls post hoc test was used. For in vivo CTL assays, a one-way ANOVA with a Student–Newman–Keuls post hoc test was used. Statistical analyses were performed using GraphPad Prism (GraphPad Software).

**Results**

*Mutating the EAT-2 SH2 domain abrogates EAT-2-mediated early activation of innate and adaptive immune cells in vivo*

We have previously demonstrated that rAd5-based vaccines expressing the SLAM family of receptors adaptor, EAT-2, trigger early activation of both innate and adaptive immune cells, activations that were positively correlated with improved induction of cellular immune responses to coadministered Ags in Ad5-naïve mice (19, 20). Several biochemical and mechanistic studies have demonstrated that SAP adaptors such as EAT-2 regulate SLAM-initiated signaling in immune cells via association of their SH2 domain to the phosphorylated immunoreceptor tyrosine-based switch motifs of SLAM receptors (31). We therefore constructed a rAd5 vector that expresses a SH2 domain mutant form of the EAT-2 adaptor (rAd5-EAT-2(R31Q)) and evaluated innate and adaptive immune cell activation following its administration into C57BL/6 mice. The location of this mutation exactly mimics a mutation in the SAP protein present in X-linked lymphoproliferative patients, a mutation that disrupts the phosphotyrosine-binding pocket of SAP adaptor, and is thus confirmed to abrogate SAP-mediated regulation of human and mouse innate and adaptive immune cells (32, 33). We first analyzed the expression of the lymphocyte activation marker CD69 in various immune cells shortly after administration of rAd5-EAT-2, rAd5-EAT-2(R31Q), or rAd5-GFP vectors into C57BL/6 mice. Consistent with our previous results (19), vaccination with rAd5-expressing WT EAT-2 induced significantly higher numbers of CD69-expressing NK (p < 0.001), CD4+ (p < 0.01), and CD8+ T (p < 0.01) cells and amounts of CD69 per cell (mean fluorescence intensity [MFI], p < 0.01) as compared with the rAd5-GFP–treated controls (Fig. 1A–C). Importantly, the activation function of EAT-2 in NK and CD8+ T cells was significantly reduced when the identical experiment was performed utilizing the rAd5 expressing the EAT-2(R31Q) mutant (Fig. 1A, 1B). Statistically significant reduction in the amount per cell (MFI, p < 0.01), but not in the number (percentages), of CD69-expressing CD4+ T cells were also observed in rAd5-EAT-2(R31Q)–injected mice as compared with WT EAT-2–expressing Ads (Fig. 1C). We also evaluated DC maturation status after rAd5 vaccinations. We observed statistically significant increases in the number and amount of CD86 (B7.1) being expressed on DCs (CD11c\textsuperscript{+}CD11b\textsuperscript{+}) in splenocytes derived from rAd5-EAT-2–injected mice as compared with rAd5-GFP–treated controls (Fig. 1D). In contrast, DCs derived from rAd5-EAT-2 (R31Q)–treated mice failed to significantly increase the number (p < 0.05) and amount (p < 0.05) of CD86-expressing DCs as compared with DCs derived from mice vaccinated with the rAd5-expressing WT EAT-2 (Fig. 1D).

*Expressing EAT-2 protein enhances the Gag-specific cellular immune responses in Ad5 immune mice*

Pre-existing anti-Ad5 immunity in human populations may significantly limit the efficacy of rAd5-based vaccine approaches (34, 35). To investigate whether the enhanced innate immune profile promoted by rAd5-mediated expression of EAT-2 could still influence the adaptive immune responses to a coadministered Ag in the presence of high levels of anti-Ad5–specific immunity (Ad5 immune mice), we performed initial dose-curve studies to identify the lowest dose of rAd5-HIV/Gag that generated detectable Gag-specific cellular immune responses in Ad5 immune mice. As a result, we identified an rAd5-HIV/Gag dose of 5 × 10^5 vps per mouse as the most relevant experimental doses for these initial studies (data not shown). We first evaluated the ability of a single immunization with rAd5-HIV/Gag and rAd5-EAT-2 to elicit cellular immune responses at 2 wk after vaccination of Ad5 immune mice. Initial CD8+ T lymphocyte responses specific for the immunogenic HIV/Gag epitope (AMQMLKETI) were determined by multiparameter tetramer-binding assays. At 11 and 17 d postinjection (dpi), significantly increased numbers of Gag-specific CD8+ T cells were observed in PBMCs derived from rAd5-HIV/Gag and rAd5-EAT-2–coimmunized Ad5 immune mice as compared with the respective cell populations isolated from rAd5-HIV/Gag–treated controls (Fig. 2A–C).

In longer term studies, we evaluated the ability of EAT-2–augmented rAd5 vaccines to induce potent Gag-specific CD8+ T lymphocyte responses following homologous rAd5-HIV/Gag prime-boost regimens in Ad5 immune mice. Two weeks following the boosting immunization, Gag-specific CD8+ T lymphocyte responses were evaluated by tetramer-binding assays. We were able to detect heightened Gag-specific tetramer-positive CD8+ T cells in PBMCs (p < 0.01) and splenocytes (p < 0.05) derived from rAd5-HIV/Gag rAd5-EAT-2–coimmunized mice as compared with the respective cell populations isolated from control mice (Fig. 3). In contrast, CD8+ T cells derived from PBMCs and splenocytes of the rAd5-HIV/Gag ’Ad-EAT-2(R31Q)–covaccinated control mice revealed significantly reduced (p < 0.05) Gag-specific tetramer-positive...
CD8+ T cells as compared with the respective cell populations derived from WT EAT-2–augmented rAd5-HIV/Gag vectors, suggesting a critical role for SH2 domain-mediated signaling in EAT-2 regulating the induction of CD8+ T cell responses during vaccination (Fig. 3). Similar statistically significant results were also observed utilizing lower doses (1 × 10^8 total vps/mouse) of the vaccine vectors 24 wk following the homologous prime-boost immunization (Fig. 2A, 2D).

We also evaluated the functional T cell memory responses following the boosting immunization by IFN-γ ELISPOT assay. Following ex vivo stimulation with the immunodominant Gag peptide (AMQMLKETI), splenocytes derived from Ad immune mice coimmunized with rAd5-HIV/Gag and rAd5-EAT-2 contained significantly (p < 0.05) increased numbers of Gag-specific IFN-γ-secreting cells as compared with similarly treated splenocytes derived from rAd5-HIV/Gag– and WT EAT-2–treated Ad immune mice (Fig. 4). Again, no statistically significant differences in the number of Gag-specific IFN-γ-secreting cells were observed between rAd5-EAT-2(R31Q)– and rAd5-GFP–coinjected animals (Fig. 4). We also evaluated anti-Ad responses by measuring Ad5-specific IFN-γ-secreting cells using an IFN-γ ELISPOT assay. Importantly, experimental and control groups revealed similar levels of Ad5-specific IFN-γ–secreting T cells at these and lower overall doses (data not shown). Humoral immune responses to HIV/Gag were also evaluated following single and homologous prime-boost immunizations. Consistent with our previous results (19, 20), inclusion of rAd5-EAT-2 in the vaccine mixture did not diminish the humoral immune responses (total Gag-specific IgG) to the HIV/Gag Ag (Supplemental Fig. 3B). We also evaluated the humoral immune responses to Ad5 following the homologous prime-boost immunization. Similarly, plasma levels of total Ad5-specific IgG were observed in the experimental and control groups (Supplemental Fig. 3C).

Expressing EAT-2 induces multiple Gag-specific T lymphocyte responses in Ad5 immune mice

The induction of increased numbers of Ag-specific T lymphocytes that express several cytokines in response to Ags correlates with
improved vaccine-induced protective immunity and positively correlates with the induction of long-lived memory responses (36, 37). Six-color flow cytometry was used to enumerate the frequency of CD8+ and CD4+ T cells producing IFN-γ, TNF-α, and/or IL-2 after ex vivo stimulation with HIV/Gag-specific peptides elicited by the use of EAT-2–augmented Ad-HIV/Gag vaccines in

![FIGURE 2.](image)

**FIGURE 2.** rAd5-HIV/Gag and rAd5-EAT-2 covaccination enhances the Gag-specific CD8+ T lymphocyte responses despite Ad5 pre-existing immunity. Ad5 preimmune BALB/c mice (n = 12) were coimmunized i.m. in the tibialis anterior with equivalent viral particles of rAd5-HIV/Gag mixed with either rAd5-EAT-2 or rAd5-GFP (total of $1 \times 10^8$ vps mixed prior to injection). PBMCs were collected from the immunized mice and stained with a PE-conjugated H2-Kd-AMQMLKETI tetramer complex together with an allophycocyanin-conjugated anti-CD3 and Pacific Blue-conjugated anti-CD8 Abs. The percentage of Gag-specific CD8+ T cells (%Tet+) is depicted. (A) Representative figures of Gag-specific tetramer+CD8+ T cells at the indicated time points are shown. (B) Gag-specific CD8+ T cell responses after prime vaccination at 11 dpi in PBMCs (pool of three mice in each group). (C) Gag-specific CD8+ T cell responses after prime vaccination at 17 dpi in PBMCs. (D) Gag-specific CD8+ T cell responses after prime-boost vaccination at week 24 in PBMCs. The bars represent means ± SD for 12 mice per group. Data were collected in an LSRII and analyzed by FlowJo software. Statistical analysis was completed using one-way ANOVA with a Student–Newman–Keuls post hoc test. A p value < 0.05 was deemed statistically significant. *p < 0.05, **p < 0.01 versus naive animals.

![FIGURE 3.](image)

**FIGURE 3.** Gag-specific CD8+ T lymphocyte responses elicited by rAd5-HIV/Gag and rAd5-EAT-2 vectors in rAd5 preimmune BALB/c mice. Ad5 preimmune BALB/c mice (n = 7) were coimmunized i.m. in the tibialis anterior with equivalent viral particles of rAd5-HIV/Gag mixed with rAd5-EAT-2, rAd5-GFP, or rAd5-EAT-2(R31Q) (total of $1 \times 10^9$ vps mixed prior to injection). HIV/Gag-specific CD8+ T lymphocyte responses from peripheral blood and spleen specific for the H2-Kd-restricted Gag epitope (AMQMLKETI) were determined at week 34 by multiparameter tetramer-binding assays. The percentage of Gag-specific CD8+ T cells (%Tet+) is depicted. At week 34, mice were sacrificed and PBMCs (A) or splenocytes (B) were harvested and stained with a PE-conjugated AMQMLKETI tetramer complex together with an allophycocyanin-conjugated anti-CD3 and Pacific Blue-conjugated anti-CD8 Abs. The bars represent means ± SD for seven mice per group for virus injected and four mice for naive animals. Data were collected in an LSRII and analyzed by FlowJo software. Statistical analysis was completed using one-way ANOVA with a Student–Newman–Keuls post hoc test. A p value < 0.05 was statistically significant. **p < 0.01 versus naive animals.
Ad5-EAT-2 VACCINE EVADES PRE-EXISTING Ad5 IMMUNITY

FIGURE 4. Magnitude of HIV/Gag-specific IFN-γ-secreting T lymphocytes following rAd5-EAT-2 covaccination of Ad5 preimmune animals. Ad5 preimmune BALB/c mice (n = 7) were subjected to a homologous prime-boost rAd5 covaccination regimen. At week 34, animals were terminally sacrificed, and splenocytes were harvested and stimulated ex vivo with the 15-mer HIV/Gag-derived immunogenic peptides AMQMLKETI, and IFN-γ ELISPOT assays were completed. Bars represent means ± SD. Statistical analysis was completed using two-way ANOVA with a Bonferroni post hoc test. A p value < 0.05 versus naive animals.

Ad5 immune mice. Our analysis revealed statistically higher numbers of HIV/Gag-specific IFN-γ+ (p < 0.05), TNF-α+ (p < 0.05), and IFN-γ/TNF-α double-positive (p < 0.05) CD8+ T cells derived from EAT-2–augmented rAd5-HIV/Gag vaccine-immunized mice as compared with mice vaccinated with control vaccines (Fig. 5A, 5C). In contrast to these robust responses, CD8+ T cells derived from mutant EAT-2(R31Q)–augmented rAd5-HIV/Gag–injected mice express significantly (p < 0.05) lower numbers of IFN-γ, TNF-α, and IFN-γ/TNF-α double-positive cells as compared with cells derived from WT EAT-2–augmented rAd5-HIV/Gag–expressing Ad5 vectors (Fig. 5B, 5D). We also attempted to detect IL-2–expressing T lymphocytes, but none was detectable to appreciable levels in both experimental and control groups (data not shown).

FIGURE 5. Cytokines secretion profiles of rAd5-HIV/Gag and rAd5-EAT-2 vaccine-elicited T lymphocytes. The cytokine secretion profiles of HIV/Gag-specific CD8+ and CD4+ T cells elicited by the homologous rAd5-HIV/Gag and rAd5-EAT-2 prime-boost covaccination regimen were determined by multiparameter intracellular cytokine staining assays. (A) Representative example of IFN-γ, TNF-α, or IFN-γ/TNF-α–producing splenic CD8+ T cells. (B) Representative example of IFN-γ, TNF-α, or IFN-γ/TNF-α–producing splenic CD4+ T cells. Gate were set based on negative control (naive) and placed consistently across samples. (C) The total frequency of splenic CD8+ T cells derived from Ad5 preimmune BALB/c mice expressing IFN-γ, TNF-α, or IFN-γ and TNF-α. (D) The total frequency of splenic CD4+ T cells derived from Ad5 preimmune BALB/c mice expressing IFN-γ, TNF-α, or IFN-γ and TNF-α. The bars represent means ± SD. Statistical analysis was completed using one-way ANOVA with a Student–Newman–Keuls post hoc test. A p value < 0.05 was deemed statistically significant. *p < 0.05 versus naive animals.
(Fig. 6C) and splenocytes (Fig. 6D) derived from the rAd-HIV/Gag– and rAd5-EAT-2–coinjected mice as compared with cells derived from mice vaccinated with the control rAd5-HIV/Gag vaccines. Mutating the EAT-2 SH2 domain completely abolished the ability of EAT-2–augmented vaccination to enhance the induction of these T<sub>CM</sub> CD8<sup>+</sup> cell responses after the boost immunization in PBMCs and splenocytes of both the experimental and control groups (Fig. 6C, 6D). No statistically significant increases in Gag-specific TEM CD8<sup>+</sup> T cells derived from peripheral blood of rAd5-GFP– or rAd5-EAT-2 (R31Q)–coinjected mice showed a predominantly TEM phenotype as compared with cells derived from the rAd5-GFP– or rAd5-EAT-2 (R31Q)–coinjected mice (Fig. 7A). Interestingly, the Gag-specific CD8<sup>+</sup> T cells derived from peripheral blood of rAd5-EAT-2–coinjected mice exhibit reduced numbers of T<sub>CM</sub> cells as compared with the control-injected mice (Fig. 7A). No significant differences in the numbers of Gag-specific T<sub>CM</sub> cells were observed in the splenocytes derived from any of the groups of treated mice at this time point (Fig. 7B). Significant reductions in the numbers of Gag-specific T<sub>CM</sub> CD8<sup>+</sup> T lymphocytes were also observed in mice derived from rAd5-EAT-2–injected mice as compared with rAd5-GFP– and rAd5-EAT-2(313Q)–vaccinated mice (Fig. 7B), suggesting that Ad-EAT-2–augmented vaccinations shifted the quality of the Ag-specific cellular immune responses to an effector memory, rather than a central memory, phenotype.

**Memory CD8<sup>+</sup> T cells of rAd5-EAT-2–vaccinated mice exhibit improved in vivo CTL activity and cytolytic degranulation**

The predominant Gag-specific T<sub>EM</sub> CD8<sup>+</sup> cell responses elicited by augmentation of vaccines with EAT-2 would predict an improved

---

**FIGURE 6.** EAT-2 expression increases the magnitude of Gag-specific T<sub>CM</sub> and T<sub>EM</sub> CD8<sup>+</sup> cell responses in Ad5 immune animals. Magnitude and phenotype analysis of HIV/Gag-specific CD8<sup>+</sup> T cells elicited by rAd5-HIV/Gag and rAd5-EAT-2 T cells were determined in peripheral blood and splenocytes of Ad5 immune mice by multiparameter tetramer-binding assays. (A) Frequency of Gag-specific tetramer-positive T<sub>CM</sub> (CD62L<sup>-</sup>CD127<sup>+</sup>) CD8<sup>+</sup> cells 2 wk following the prime vaccination with 1 \times 10<sup>9</sup> vps is shown. (B) Frequency of Gag-specific tetramer-positive T<sub>EM</sub> (CD62L<sup>-</sup>CD127<sup>-</sup>) CD8<sup>+</sup> cells 2 wk following the prime vaccination with 1 \times 10<sup>9</sup> vps is shown. (C) Frequency of Gag-specific tetramer-positive T<sub>EM</sub> (CD62L<sup>-</sup>CD127<sup>-</sup>) CD8<sup>+</sup> cells in PBMCs 34 wk following the homologous prime-boost vaccination with 1 \times 10<sup>9</sup> vps is shown. (D) Frequency of Gag-specific tetramer-positive T<sub>EM</sub> CD8<sup>+</sup> cells in splenocytes 34 wk following the homologous prime-boost vaccination with 1 \times 10<sup>9</sup> vps is shown. The bars represent means \pm SD. Statistical analysis was completed using one-way ANOVA with a Student–Newman–Keuls post hoc test. A p value < 0.05 was deemed statistically significant. *p < 0.05 versus naive animals.

**FIGURE 7.** Phenotype analysis of HIV/Gag-specific CD8<sup>+</sup> T cells following the homologous prime-boost vaccination of rAd5-HIV/Gag and rAd5-EAT-2. Phenotype analysis of HIV/Gag-specific CD8<sup>+</sup> T cells elicited by the homologous rAd5-HIV/Gag and rAd5-EAT-2 prime-boost covaccination regimen were determined at week 34 in peripheral blood and splenocytes by multiparameter tetramer-binding assays. (A) Percentages of Gag-specific T<sub>EM</sub> and T<sub>CM</sub> CD8<sup>+</sup> T cells in PBMCs are shown. (B) Percentages of Gag-specific T<sub>EM</sub> and T<sub>CM</sub> CD8<sup>+</sup> T cells in splenocytes are shown. The bars represent means \pm SD. Statistical analysis was completed using one-way ANOVA with a Student–Newman–Keuls post hoc test. A p value < 0.05 was deemed statistically significant. *p < 0.05 versus naive animals.
potential for induction of functional, Ag-specific cytotoxic T cell activity (38). We initially evaluated the surface mobilization (expression) of CD107a (LAMP-1) in vitro culture of splenocytes (derived from Ad5 preimmune mice coimmunized with rAd5-HIV/Gag and rAd5-EAT-2) in the presence of the immunodominant AMQMLKETI–Gag peptide. Our results revealed that CD8+ T lymphocytes derived from rAd5-HIV/Gag– and rAd5-EAT-2–coimmunized mice express significantly higher levels of CD107a (p < 0.05) as compared with cells derived from the control vaccines (Fig. 8A). Six-color flow cytometry was then used to enumerate the frequency of granzyme B and perforin-producing TCM and TEM CD8+ lymphocytes. We observed statistically significant increases in the number (p < 0.05) and amount per cell (MFI, p < 0.05) of Gag-specific granzyme B–producing total T (Fig. 8B), TCM (Fig. 8C), and TEM (Fig. 8D) CD8+ lymphocytes derived from EAT-2–augmented rAd5-HIV/Gag vaccine-immunized mice as compared with mice vaccinated with control vaccines. Analysis of perforin-expressing CD8+ T cells of rAd5-EAT-2–coinjected mice trended to also increase, but no statistically significant differences were observed between the experimental and control groups (data not shown).

To investigate whether these Gag-specific TEM-skewed T cells also possess enhanced in vivo cytolytic activity toward Ag-presenting target cells, Ad5 preimmune BALB/c mice were primed i.m. with 1 × 109 total vps of the rAd-HIV/Gag+ Ad-EAT-2, rAd-HIV/Gag+ Ad-EAT-2(R31Q), or rAd5-HIV/Gag+ rAd5-GFP control vaccine formulations. Mice were then boosted with the same rAd5 vectors at week 32. Two weeks following the boost immunization, the three groups of mice were then injected with CFSE-labeled syngeneic splenocytes previously pulsed with the Gag-derived peptides AMQMLKETI or an irrelevant peptide (see Materials and Methods). Consistent with the results obtained in Ad5-naïve animals (19, 20), HIV/Gag-specific CTL activities induced in Ad immune mice coimmunized with rAd5-HIV/Gag and rAd5-EAT-2 were significantly higher as compared with control mice (Fig. 9). Importantly, rAd5-EAT-2(R31Q)–coinjected mice exhibited significantly reduced cytolytic activity, as compared with mice coinjected with the WT EAT-2–expressing Ad5 vaccine vectors (Fig. 9).

Discussion

The development of an effective vaccine against HIV-1 remains elusive. Various reports in vaccinated nonhuman primates challenged with SIV suggest that putative HIV-1 vaccines should elicit potent, and durable, HIV-1–specific TEM CD8+ cell responses so as to provide protection in the earliest stages following HIV-1 infection (8–10). The promising results from recent HIV-1 vaccine trials support the need to continue attempts to enhance the potency of HIV-1–targeted vaccine platforms (39). Recombinant Ad5-based vaccines have been the focus of considerable interest for their potential application in HIV-1 vaccine development; however, early generation rAd5 platforms failed to protect vaccinees from HIV-1 infection (4, 40). One hypothesis suggests that the rAd5-based vaccine failure was due to the presence of pre-existing anti-Ad5–specific immunity (23, 39). We have previously demonstrated that rAd5-based vector vaccines expressing the SLAM family of receptors adaptor, EAT-2, induced potent cellular immune responses to a coadministered HIV-1 Gag Ag in Ad5-naïve animals (19). In this study, we now demonstrate that rAd5-EAT-2 vectors also induce potent Gag-specific T cell responses in Ad5 immune mice, responses that persisted for >200 d.

Some reports have shown that nonreplicating vaccine vectors induce primarily TCM responses (10). In this study, we evaluated the phenotype and functionality of vaccine-elicited cellular immune responses 3 wk following rAd-HIV/Gag– and rAd5-EAT-2–augmented prime-boost immunizations. Our data revealed that Gag-specific T lymphocytes derived from rAd5-EAT-2–vaccinated mice exhibit improved cytolytic degranulation. Ad5 preimmune BALB/c mice (n = 6) were subjected to a homologous prime-boost rAd5 vaccination regimen. At week 24, splenocytes from Ad5 preimmune BALB/c mice of rAd5-HIV/Gag– and rAd5-EAT-2–coinoculated or control groups were in vitro cultured in the presence or absence of the immunogenic Gag-specific peptide AMQMLKETI. At 72 h after infection, cells were stained with allophycocyanin-conjugated anti-CD3, Pacific Blue-conjugated anti-CD8, or FITC-conjugated anti-CD107. **(A) Frequency and MFI of perforin-expressing CD8+ T cells from rAd5-HIV/Gag– and rAd5-EAT-2–vaccinated mice exhibit improved cytolytic degranulation. Ad5 preimmune BALB/c mice (n = 6) were subjected to a homologous prime-boost rAd5 vaccination regimen. (A) At week 24, splenocytes from Ad5 preimmune BALB/c mice of rAd5-HIV/Gag– and rAd5-EAT-2–coinoculated or control groups were in vitro cultured in the presence or absence of the immunogenic Gag-specific peptide AMQMLKETI. At 72 h after infection, cells were stained with allophycocyanin-conjugated anti-CD3, Pacific Blue-conjugated anti-CD8, or FITC-conjugated anti-CD107.**

**FIGURE 8.** Gag-specific CD8+ T cells from rAd5-HIV/Gag– and rAd5-EAT-2–vaccinated mice exhibit improved cytolytic degranulation. Ad5 preimmune BALB/c mice (n = 6) were subjected to a homologous prime-boost rAd5 vaccination regimen. (A) At week 24, splenocytes from Ad5 preimmune BALB/c mice of rAd5-HIV/Gag– and rAd5-EAT-2–coinoculated or control groups were in vitro cultured in the presence or absence of the immunogenic Gag-specific peptide AMQMLKETI. At 72 h after infection, cells were stained with allophycocyanin-conjugated anti-CD3, Pacific Blue-conjugated anti-CD8, or FITC-conjugated anti-CD107. (B) Frequency and MFI of perforin-expressing CD8+ T cells from rAd5-HIV/Gag– and rAd5-EAT-2–vaccinated mice exhibit improved cytolytic degranulation. (C) Frequency and MFI of perforin-expressing CD8+ T cells from rAd5-HIV/Gag– and rAd5-EAT-2–vaccinated mice exhibit improved cytolytic degranulation. (D) Frequency and MFI of perforin-expressing CD8+ T cells from rAd5-HIV/Gag– and rAd5-EAT-2–vaccinated mice exhibit improved cytolytic degranulation. **(A)** Frequency and MFI of perforin-expressing CD8+ T cells from rAd5-HIV/Gag– and rAd5-EAT-2–vaccinated mice exhibit improved cytolytic degranulation.

**FIGURE 8.** Gag-specific CD8+ T cells from rAd5-HIV/Gag– and rAd5-EAT-2–vaccinated mice exhibit improved cytolytic degranulation. Ad5 preimmune BALB/c mice (n = 6) were subjected to a homologous prime-boost rAd5 vaccination regimen. (A) At week 24, splenocytes from Ad5 preimmune BALB/c mice of rAd5-HIV/Gag– and rAd5-EAT-2–coinoculated or control groups were in vitro cultured in the presence or absence of the immunogenic Gag-specific peptide AMQMLKETI. At 72 h after infection, cells were stained with allophycocyanin-conjugated anti-CD3, Pacific Blue-conjugated anti-CD8, or FITC-conjugated anti-CD107. (B) Frequency and MFI of perforin-expressing CD8+ T cells from rAd5-HIV/Gag– and rAd5-EAT-2–vaccinated mice exhibit improved cytolytic degranulation. (C) Frequency and MFI of perforin-expressing CD8+ T cells from rAd5-HIV/Gag– and rAd5-EAT-2–vaccinated mice exhibit improved cytolytic degranulation. (D) Frequency and MFI of perforin-expressing CD8+ T cells from rAd5-HIV/Gag– and rAd5-EAT-2–vaccinated mice exhibit improved cytolytic degranulation.

By guest on January 21, 2018 http://www.jimmunol.org/ Downloaded from
CFSEhigh/% CFSELow populations 20 h after adoptive transfer into naive or coimmunized mice in splenocytes are shown. (A) Representative figures of percentages of CFSE<sup>low</sup> and CFSE<sup>high</sup> populations 20 h after adoptive transfer into naive or coimmunized mice in splenocytes are shown. (B) Statistical analysis of percentage specific killing is shown. Percentage CFSE<sup+</sup> cells were quantified using FlowJo software. Percentage specific killing = 1 – [% CFSE<sup>high</sup>/ % CFSE<sup>low</sup>]<sub>immunized</sub>/[% CFSE<sup>high</sup>/ % CFSE<sup>low</sup>]<sub>naive</sub>. ***p < 0.001 versus naive animals.

Results from IFN-γ ELISPOT assay revealed that Gag-specific IFN-γ-secreting T cell responses are lower in magnitude than those induced by a single rAd5-HIV/Gag and rAd5-EAT-2 immunization of rAd5-naive animals (19), presumably as a result of the development of Ad5-specific T cells and neutralizing Abs generated by the priming immunization (19). Despite this, vaccination with rAd5-HIV/Gag along with EAT-2 overexpression still generates superior T cell responses as compared with the control-vaccinated Ad5 immune animals. Additionally, FACS intracellular staining analysis of Gag-specific CD<sup>8+</sup> T cells revealed equal frequencies of IFN-γ– and TNF-α–producing CD<sup>8+</sup> T cells in splenocytes derived from Ad5-naive (19) and Ad5 immune BALB/c mice coimmunized with EAT-2–augmented Ad5-HIV/Gag vaccines.

Although we did note improved inductions of Gag Ag-specific immune responses, we did not observe significant increases in anti-Ad–specific cellular immune responses in Ad5-EAT-2–immunized mice. This could be due to the fact that E1-deleted Ad vectors minimally express potentially immunogenic Ad5 genes, especially when compared with the high and sustained expression levels of the Gag Ag, which was under the control of the strong CMV enhancer/promoter element. However, we cannot rule out the possibility that EAT-2 did alter immune responses to Ad5 in a manner that could not be detected by the assays that we used in our studies.

Finally, although the mechanism as to how the rAd5-EAT-2 platform evaded anti-Ad5 immunity is not identified in this study, one possibility may be that despite the presence of high amounts of neutralizing Abs in the serum, these Abs are not present at high enough concentrations to fully prevent Ad transduction of APCs at the vaccination site. This, combined with an enhanced induction of innate immune responses by expression of EAT-2 from these Ad vectors successfully transducing APCs in the Ad5 immune animal, may allow for induction of beneficial innate immune responses that result in higher magnitude cellular immune responses to a coex-
pressed Ag, responses that remain functional and detectable for extended periods of time in Ad5 preimmune mice.

In conclusion, our results clearly establish that EAT-2 expression by vaccine platforms can significantly improve vaccine-elicited T$_{h}$MD CD8$^+$ cell responses in general, and can provide a new approach for enhancing the efficacy of Ad5-based vaccines against HIV-1 specifically. Our findings also demonstrate that vaccine vectors that express EAT-2 during Ag vaccination can serve to improve the ability of a vaccine to stimulate the innate immune system, and subsequently induce potent multifunctional Ag-specific cellular immune responses even in the face of pre-existing immunity to the vaccine vector.

Acknowledgments

We thank Michigan State University Laboratory Animal Support Facilities for assistance in the humane care and maintenance of the animals used in this work.

Disclosures

The authors have no financial conflicts of interest.

References